Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Concepts in Pharmacogenomics and Personalized Medicine
29
100. Locharernkul, C., et al. Carbamazepine and phenytoin induced Stevens-Johnson
syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia, 2008;
49(12): 2087–91.
101. Kuehn, B.M. FDA: Epilepsy drugs may carry skin risks for Asians. JAMA, 2008;
300(24): 2845.
102. Yang, C.W., et al. HLA-B*1502-bound peptides: Implications for the pathogenesis of
carbamazepine-induced Stevens-Johnson syndrome. J Allergy Clin Immunol, 2007;
120(4): 870–7.
103. Hirsch, L.J., et al. Cross-sensitivity of skin rashes with antiepileptic drug use.
Neurology, 2008; 71(19): 1527–34.
104. Alvestad, S., S. Lydersen, and E. Brodtkorb. Cross-reactivity pattern of rash from
current aromatic antiepileptic drugs. Epilepsy Res, 2008; 80(2–3): 194–200.
105. Leckband, S.G., et al. Clinical Pharmacogenetics Implementation Consortium guidelines
for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther, 2013;
94(3): 324–8.
106. Codeine sulfate tablets. Prescribing information. 2009. Available from: http://
www.accessdata.fda.gov/drugsatfda_docs/label/2009/022402s000lbl.pdf (accessed
August 30, 2011).
107. Caraco, Y., et al. Microsomal codeine N-demethylation: Cosegregation with cytochrome
P4503A4 activity. Drug Metab Dispos, 1996; 24(7): 761–4.
108. Dayer, P., et al. Bioactivation of the narcotic drug codeine in human liver is mediated
by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome
P-450 dbl/bufI). Biochem Biophys Res Commun, 1988; 152(1): 411–16.
109. Kirchheiner, J., et al. Pharmacokinetics of codeine and its metabolite morphine in
ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomics J, 2007; 7(4):
257–65.
110. Ingelman-Sundberg, M., et al. Influence of cytochrome P450 polymorphisms on drug
therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol
Ther, 2007; 116(3): 496–526.
111. Lurcott, G. The effects of the genetic absence and inhibition of CYP2D6 on the metabolism
of codeine and its derivatives, hydrocodone and oxycodone. Anesth Prog, 1998;
45(4): 154–6.
112. Murphy, M.P., et al. Prospective CYP2D6 genotyping as an exclusion criterion for
enrollment of a phase III clinical trial. Pharmacogenetics, 2000; 10(7): 583–90.
113. Borges, S., et al. Composite functional genetic and comedication CYP2D6 activity
score in predicting tamoxifen drug exposure among breast cancer patients. J Clin
Pharmacol, 2010; 50(4): 450–8.
114. Gaedigk, A., et al. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment
using a genotyping algorithm based on allele frequency data. Pharmacogenetics,
1999; 9(6): 669–82.
115. Gaedigk, A., et al. The CYP2D6 activity score: Translating genotype information into
a qualitative measure of phenotype. Clin Pharmacol Ther, 2008; 83(2): 234–42.
116. Zanger, U.M., S. Raimundo, and M. Eichelbaum. Cytochrome P450 2D6: Overview
and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch
Pharmacol, 2004; 369(1): 23–37.
117. Sindrup, S.H., et al. Codeine increases pain thresholds to copper vapor laser stimuli
in extensive but not poor metabolizers of sparteine. Clin Pharmacol Ther, 1990;
48(6): 686–93.
118. Eckhardt, K., et al. Same incidence of adverse drug events after codeine administration
irrespective of the genetically determined differences in morphine formation. Pain,
1998; 76(1–2): 27–33.